Abstract
Osteoporosis is a major health issue. By 2050, a greater than 2-fold increase in patients number with hip fractures will occur in Asia representing 50% of all hip fractures worldwide. For the Asia-Pacific (AP) region, more efforts on controlling osteoporosis and the subsequent fractures are crucial. Bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) is commonly used to diagnose osteoporosis and monitor osteoporosis treatment. However, the inconvenience, cost, limited availability of DXA and the delay in detection of BMD changes after treatment initiation support an important role for bone turnover markers (BTMs), as short-term tools to monitor therapy. With regards to low adherence rates of medical treatment of osteoporosis, the experts reached consensus on the use of BTMs for both raising awareness and short-term monitoring of osteoporosis treatment in the AP region. The experts endorse the use of BTMs, especially serum C-terminal telopeptide of type 1 collagen (CTX) and serum procollagen type 1 N propeptide (P1NP), as short-term monitoring tools to help clinicians assess the responses to osteoporosis therapies and appropriately adjust treatment regimens earlier than BMD. Either the absolute values or the degree of change from baseline in BTMs can be used to monitor the potential efficacy of osteoporosis therapies. The use of BTMs can be incorporated in osteoporosis care programs, such as fracture liaison service (FLS), to improve patient adherence and treatment outcomes. Encouraging sufficient reimbursement from health care systems may facilitate widespread use of BTMs in clinical practice in the AP region.
| Original language | English |
|---|---|
| Journal | Journal of Clinical Densitometry |
| DOIs | |
| Publication status | Published - 2019 Jan 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Endocrinology, Diabetes and Metabolism
- Orthopedics and Sports Medicine
- Radiology Nuclear Medicine and imaging
Cite this
}
Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region. / Wu, Chih-Hsing; Chang, Yin-Fan; Chen, Chung Hwan; Lewiecki, E. Michael; Wüster, Christian; Reid, Ian; Tsai, Keh Sung; Matsumoto, Toshio; Mercado-Asis, Leilani B.; Chan, Ding Cheng; Hwang, Jawl Shan; Cheung, Ching Lung; Saag, Kenneth; Lee, Joon Kiong; Tu, Shih Te; Xia, Weibo; Yu, Wei; Chung, Yoon Sok; Ebeling, Peter; Mithal, Ambrish; Ferrari, Serge Livio; Cooper, Cyrus; Lin, Gau Tyan; Yang, Rong Sen.
In: Journal of Clinical Densitometry, 01.01.2019.Research output: Contribution to journal › Article
TY - JOUR
T1 - Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region
AU - Wu, Chih-Hsing
AU - Chang, Yin-Fan
AU - Chen, Chung Hwan
AU - Lewiecki, E. Michael
AU - Wüster, Christian
AU - Reid, Ian
AU - Tsai, Keh Sung
AU - Matsumoto, Toshio
AU - Mercado-Asis, Leilani B.
AU - Chan, Ding Cheng
AU - Hwang, Jawl Shan
AU - Cheung, Ching Lung
AU - Saag, Kenneth
AU - Lee, Joon Kiong
AU - Tu, Shih Te
AU - Xia, Weibo
AU - Yu, Wei
AU - Chung, Yoon Sok
AU - Ebeling, Peter
AU - Mithal, Ambrish
AU - Ferrari, Serge Livio
AU - Cooper, Cyrus
AU - Lin, Gau Tyan
AU - Yang, Rong Sen
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Osteoporosis is a major health issue. By 2050, a greater than 2-fold increase in patients number with hip fractures will occur in Asia representing 50% of all hip fractures worldwide. For the Asia-Pacific (AP) region, more efforts on controlling osteoporosis and the subsequent fractures are crucial. Bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) is commonly used to diagnose osteoporosis and monitor osteoporosis treatment. However, the inconvenience, cost, limited availability of DXA and the delay in detection of BMD changes after treatment initiation support an important role for bone turnover markers (BTMs), as short-term tools to monitor therapy. With regards to low adherence rates of medical treatment of osteoporosis, the experts reached consensus on the use of BTMs for both raising awareness and short-term monitoring of osteoporosis treatment in the AP region. The experts endorse the use of BTMs, especially serum C-terminal telopeptide of type 1 collagen (CTX) and serum procollagen type 1 N propeptide (P1NP), as short-term monitoring tools to help clinicians assess the responses to osteoporosis therapies and appropriately adjust treatment regimens earlier than BMD. Either the absolute values or the degree of change from baseline in BTMs can be used to monitor the potential efficacy of osteoporosis therapies. The use of BTMs can be incorporated in osteoporosis care programs, such as fracture liaison service (FLS), to improve patient adherence and treatment outcomes. Encouraging sufficient reimbursement from health care systems may facilitate widespread use of BTMs in clinical practice in the AP region.
AB - Osteoporosis is a major health issue. By 2050, a greater than 2-fold increase in patients number with hip fractures will occur in Asia representing 50% of all hip fractures worldwide. For the Asia-Pacific (AP) region, more efforts on controlling osteoporosis and the subsequent fractures are crucial. Bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) is commonly used to diagnose osteoporosis and monitor osteoporosis treatment. However, the inconvenience, cost, limited availability of DXA and the delay in detection of BMD changes after treatment initiation support an important role for bone turnover markers (BTMs), as short-term tools to monitor therapy. With regards to low adherence rates of medical treatment of osteoporosis, the experts reached consensus on the use of BTMs for both raising awareness and short-term monitoring of osteoporosis treatment in the AP region. The experts endorse the use of BTMs, especially serum C-terminal telopeptide of type 1 collagen (CTX) and serum procollagen type 1 N propeptide (P1NP), as short-term monitoring tools to help clinicians assess the responses to osteoporosis therapies and appropriately adjust treatment regimens earlier than BMD. Either the absolute values or the degree of change from baseline in BTMs can be used to monitor the potential efficacy of osteoporosis therapies. The use of BTMs can be incorporated in osteoporosis care programs, such as fracture liaison service (FLS), to improve patient adherence and treatment outcomes. Encouraging sufficient reimbursement from health care systems may facilitate widespread use of BTMs in clinical practice in the AP region.
UR - http://www.scopus.com/inward/record.url?scp=85064464601&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064464601&partnerID=8YFLogxK
U2 - 10.1016/j.jocd.2019.03.004
DO - 10.1016/j.jocd.2019.03.004
M3 - Article
JO - Journal of Clinical Densitometry
JF - Journal of Clinical Densitometry
SN - 1094-6950
ER -